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The YAP and TAZ paralogues are transcriptional co-activators recruited to target sites, 
primarily by TEAD proteins.  Here, we show that YAP and TAZ are also recruited by 
JUNB and STAT3, key factors that mediate an epigenetic switch linking inflammation 
to cellular transformation. YAP and TAZ directly interact with JUNB and STAT3 via a 
WW domain important for transformation, co-occupy many target sites in vivo via AP-
1 and (to a lesser extent) STAT3 sequence motifs, and stimulate transcriptional 
activation by AP-1 proteins.  A few target sites are YAP- or TAZ-specific, and they are 
associated with different sequence motifs and gene classes.  YAP/TAZ, JUNB, and 
STAT3 directly regulate a common set of target genes that overlap, but are distinct 
from, those regulated by YAP/TAZ and TEADs. The set of genes regulated by 
YAP/TAZ, STAT3, and JUNB is associated with poor survival in breast cancer patients 
with the triple-negative form of the disease.  
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The Hippo signal transduction pathway plays critical roles in development, homeostasis 
and tumor progression (Piccolo et al., 2014; Varelas, 2014; Yu et al., 2015; Totaro et al., 
2018; Moya and Halder, 2019). Internal and external signals relayed through the Hippo 
pathway converge on YAP and TAZ, paralogous proteins with 63% sequence similarity that 
are the major effectors of this pathway (Piccolo et al., 2014; Totaro et al., 2018; Ma et al., 
2019). Once activated, YAP/TAZ translocate into nucleus and act as transcriptional co-
activators, most notably by interacting with the TEAD family of DNA-binding transcription 
factors (Piccolo et al., 2014; Totaro et al., 2018; Ma et al., 2019; Moya and Halder, 2019). 
Deregulation of YAP/TAZ activity is frequently observed in various human cancers, 
contributing to cancer initiation, progression, and metastasis (Johnson and Halder, 2014; Yu 
et al., 2015; Zanconato et al., 2016). YAP/TAZ activation is also linked to chemo-resistance 
in cancer therapy (Johnson and Halder, 2014; Yu et al., 2015; Zanconato et al., 2016). 
However, the transcriptional mechanisms and regulatory circuits mediated by YAP/TAZ in 
cancers, especially those beyond their association with TEAD1-4, are not well understood.  
 In addition to directly interacting with the TEAD family of DNA-binding proteins, 
YAP/TAZ can function through other mechanisms.  Via its interaction with TEAD proteins, 
YAP/TAZ can synergize with JUN/FOS at composite regulatory elements containing both 
TEAD and AP-1 motifs (Zanconato et al., 2015).  YAP can form a functional complex with 
β-catenin and TBX5 in cancer cells (Rosenbluh et al., 2012), YAP/TAZ can integrate into a 
SMAD-OCT4 complex in embryonic stem cells (Beyer et al., 2013), and a YAP-p73 
complex plays a role in the DNA damage response (Beyer et al., 2013).  In addition, 
YAP/TAZ directly interacts with the general co-activator BRD4 to increase RNA polymerase 
II recruitment and transcription of target genes (Zanconato et al., 2018), and YAP/TAZ 
activity is inhibited by a direct interaction with the SWI/SNF complex via the ARID1A 
subunit (Chang et al., 2018). 
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 In previous work, we described an epigenetic switch that transforms breast cells via the 
inflammatory regulatory network controlled by the joint action of NF-κB, STAT3, and AP-1 
transcription factors (Iliopoulos et al., 2009; Iliopoulos et al., 2010; Ji et al., 2018; Ji et al., 
2019). Here, we show that YAP and TAZ are important for cellular transformation in this 
breast cell transformation model. We demonstrate that YAP and TAZ directly interact with 
STAT3 and JUNB and act as transcriptional co-activators that stimulate expression of target 
genes. These target genes overlap with, but are distinct from, the target genes in which 
YAP/TAZ is recruited by TEAD proteins. The YAP/TAZ target genes mediated by 
STAT3/AP-1, but not TEAD proteins, are associated with poor survival prognosis in breast 
cancer patients with the triple-negative form of the disease. 
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YAP and TAZ are important for STAT3 and AP-1 activity during breast epithelial cell 
transformation 
We examined the role of YAP and TAZ in breast cellular transformation by using CRISPR to 
knock out these genes in the context of our Src-inducible model. Knockout of YAP or TAZ 
or both (Figure 1A) reduces growth under conditions of low attachment (Figure 1B) and 
inhibits colony formation in soft agar (Figure 1C). In contrast, there is no effect on cell 
proliferation under standard conditions of high attachment (Figure 1D). Similar results are 
observed when YAP or TAZ expression is knocked down by siRNA (Figure 1E-G). Thus, 
YAP and TAZ are important for cellular transformation in this model. 
 An inflammatory regulatory network mediated by the joint action of NF-κB, STAT3, 
and AP-1 factors at common target sites is critical for transformation in our inducible model, 
and the network is involved in many human cancers (Ji et al., 2019). Using siRNA-mediated 
knockdowns, we examined whether YAP and TAZ are important for the increased activity of 
these transcription factors during transformation. Transient knockdown of YAP and/or TAZ, 
but not JUNB, strongly decreases STAT3 phosphorylation at Tyr705 (STAT3-p, a marker of 
STAT3 activation) during transformation (Figure 2A), but it does not affect overall levels of 
STAT3 protein (Figure 2A) or mRNA (Figure 2-figure supplement 1). Consistent with this 
observation, YAP and TAZ are important for induction of IL6 transcription and secretion 
during transformation (Figure 2B). In addition, depletion of YAP or TAZ (and also STAT3 
or JUNB) inhibits transcriptional activation mediated by AP-1 factors (Figure 2C). In 
contrast, YAP or TAZ depletion causes a slight increase in NF-κB activation (Figure 2D), 
perhaps reflecting competition between the Hippo and NF-κB signaling pathways. The 
effects of YAP and TAZ on AP-1 and STAT3 activity during transformation are not due to 
changes in YAP or TAZ protein levels in the nucleus (Figure 3A).  
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YAP and TAZ directly interact with JUNB and STAT3 during transformation 
The effects of YAP and TAZ knockout on STAT3 and AP-1 activity could be direct, or they 
could be an indirect consequence of inhibiting transformation. Among the many members of 
the AP-1 transcription factor family, expression of JUNB is most strongly induced during 
transformation (Figure 3-figure supplement 1A), leading us to study JUNB in more detail. 
We addressed the possibility of a direct effect by co-immunoprecipitation (co-IP) 
experiments in cytoplasmic, nucleoplasm, and chromatin fractions from non-transformed and 
transformed cells. YAP and TAZ proteins are observed in all three cellular fractions, and 
their levels are unchanged upon tamoxifen treatment (Figure 3A and Figure 3-figure 
supplement 1B). This indicates that the Hippo pathway is active in this cell line prior to 
transformation and is not altered during the transformation process. In the nucleoplasm and 
chromatin (but not cytoplasm) fractions, YAP and TAZ each co-immunoprecipitate with 
STAT3 and JUNB (Figure 3B). In general, co-IP is more efficient in transformed cells. We 
confirmed direct pairwise YAP-STAT3, TAZ-STAT3, YAP-JUNB, and TAZ-JUNB 
interactions by performing co-IP experiments using histidine-tagged recombinant proteins 
generated in E. coli (Figure 3C).  
 
WW domains of YAP and TAZ are important for interacting with STAT3 and JUNB 
and for transformation 
YAP and TAZ have a TEAD domain that interacts with TEAD1-4, and they contain WW 
domains (two for YAP and one for TAZ) that mediate interactions with a variety of other 
proteins. To map the regions of YAP and TAZ required for interacting with STAT3 and 
JUNB, we performed co-IP experiments in cells co-expressing YAP or TAZ derivatives 
lacking one or both of these WW domains along with FLAG-tagged STAT3 or JUNB 
(Figure 3D). The WW1 domain of YAP and the WW domain of TAZ are critical for the 
interaction with STAT3 and JUNB, whereas removal of the YAP WW2 domain has no effect 
on these interactions. Removal of any WW domain has no effect on the interaction with the 
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TEAD proteins, whereas removal of the TEAD domain abolishes the interaction with the 
TEAD proteins. In addition, the TEAD domains of both YAP and TAZ are critical for the 
interaction with JUNB, but they contribute only partially to the interaction with STAT3 
(Figure 3D). When overexpressed in parental MCF-10A cells (i.e., lacking the ER-Src 
protein), wild-type YAP or TAZ increase the level of transformation, whereas derivatives 
lacking YAP-WW1 or TAZ-WW do not (Figure 3E). Like the wild-type proteins, none of 
these derivatives have a significant effect on cell proliferation under conditions of high 
attachment (Figure 3-figure supplement 1C). Thus, the WW1 domain in YAP and the WW 
domain in TAZ, which are critical for interaction with JUNB and STAT3 but not TEAD 
proteins, are important for transformation. These observations indicate that YAP and TAZ 
interactions with TEAD proteins are not sufficient for transformation, and they suggest that 
the YAP and TAZ interactions with JUNB and/or STAT3 are important for transformation.  
 
YAP and TAZ have highly similar, but not identical, genomic binding profiles  
Using protein-specific antibodies, we performed ChIP-seq to identify the genomic target sites 
of YAP, TAZ, STAT3, JUNB, and TEAD in both non-transformed and transformed cells. In 
general, there is excellent agreement in genome-wide signal profiles between pairs of 
biological replicates for each factor (Table S1A), and the binding regions of the three 
sequence-specific transcription factors—STAT3, JUNB, and TEAD—are strongly enriched 
in their respective motifs (Figure 4-figure supplement 1). YAP, TAZ, JUNB, and TEAD each 
have similar numbers of peaks in the non-transformed and transformed conditions, while 
STAT3 binding sites increase five-fold upon transformation (Table S1B).  As expected from 
their being paralogues, YAP and TAZ have very similar binding profiles in both the 
transformed and non-transformed states (Figure 4A; overall Pearson correlation coefficient 
~0.7).  For most subsequent analyses, we will consider these shared YAP/TAZ sites together. 
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YAP- and TAZ-specific sites differ in their associated motifs and biological functions 
from share YAP/TAZ sites 
 Unexpectedly, ~575 target sites (~2% of YAP/TAZ sites) appear specific for either 
YAP or TAZ (Figure 4A). To test whether these apparent YAP- or TAZ-specific sites are 
false positives or false negatives, we knocked out YAP and TAZ separately in ER-Src cells 
and then performed ChIP-seq experiments using an antibody that recognizes both proteins 
(Figure 4B). When compared to the parental cell line, a YAP-specific site should show 
reduced binding only in the YAP-deletion line, and a TAZ-specific site should show reduced 
binding only in the TAZ-deletion line. In this manner, we confirmed ~450 TAZ-specific sites 
and ~125 YAP-specific sites (Figure 4C). 
 Several characteristics of these YAP- and TAZ-specific sites suggest they serve 
biologically distinct functions from shared sites. First, > 80% of YAP- and TAZ-specific 
sites are located within 150 base pairs upstream of a GENCODE-annotated transcription start 
site (TSS), but < 25% of shared YAP/TAZ sites are so localized (Figure 4D). Second, YAP- 
and TAZ-specific sites are much less likely to be located within JUNB target regions (Chi-
square p-value=3.2×10-24 for YAP, 2.1×10-81 for TAZ) and TEAD (Chi-square p-
value=0.002 for YAP, 9.7×10-20 for TAZ) than shared YAP/TAZ sites (Figure 4E). Third, 
GO analysis of the genes whose promoters are near YAP- and TAZ-specific sites identify 
translation, rRNA processing, and mitochondrial gene expression as overrepresented gene 
categories for TAZ-specific sites, and transcriptional regulation and chromatin remodeling as 
categories overrepresented for YAP-specific sites (Table S2). Fourth, the TAZ-specific peaks 
are enriched in unique motifs (Figure 4-figure supplement 1 and see below). 
 
YAP and TAZ co-occupy genomic target sites with STAT3, JUNB, and TEAD proteins  
We compared the YAP/TAZ binding data with that of STAT3, JUNB, and TEAD proteins 
(Figure 5A, Figure 5-figure supplement 1A). As expected, about 90% of the TEAD target 
sites are also bound by YAP or TAZ. Meanwhile, 55% of STAT3 and 42% of JUNB target 
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sites are bound by YAP/TAZ, and reciprocally, 55% of YAP/TAZ peaks are bound by 
STAT3 or JUNB (Figure 5A). These co-occurrences are highly significant because a control 
set of comparable DNase hypersensitivity sites (DHSs) that are not bound YAP/TAZ show 
far lower co-occurrence of these transcription factors (Figure 5B).  TEAD, STAT3, or JUNB 
are present, respectively in 3%, 9%, and 19% of control DHSs compared with 40%, 23%, 
and 42% of YAP/TAZ sites (Chi-square p-value <10-100 for all comparisons; Figure 5B).  
Together with the physical interactions among these proteins (Figure 3B, C), these 
observations strongly suggest that YAP/TAZ co-occupy genomic sites with STAT3 and 
JUNB. 
 We further investigated protein co-occupancy by performing pairwise analysis of ChIP-
seq peak summits. For biological replicates of a given protein in transformed cells, the 
median distances between corresponding peak summits are between 8-35 bp, and this serves 
as a control. YAP and TAZ peak summits are separated by 25 bp, indicating that these two 
proteins occupy the same sequences, although not necessarily at the same time (Figure 5C). 
Interestingly, the median distances between pairwise combinations of YAP or TAZ with 
STAT3 or JUNB range between 31-44 bps (Figure 5C), indicating that YAP and TAZ 
binding occurs very close to the location of STAT3 and JUNB. Similar results are observed 
in non-transformed cells (Figure 5-figure supplement 1B). 
 We demonstrated co-occupancy of YAP and TAZ with STAT3 and JUNB by 
sequential ChIP experiments at selected loci. At the IL-6 enhancer, sequential ChIP in either 
order yields increased fold-enrichments of YAP (Figure 5D) or TAZ (Figure 5E) with JUNB 
or STAT3 in non-transformed and transformed cells; similar results are observed at the 
SNX24 locus (Figure 5-figure supplement 1C). At the MYC locus, increased fold-enrichment 
is generally seen only in one direction (JUNB or STAT3 first, with the exception of TAZ and 
STAT3; Figure 5-figure supplement 1C-D), suggesting that most of the YAP and TAZ 
binding is not mediated by JUNB or STAT3, although they can co-occupy the locus. In 
addition, sequential ChIP (in both orders) of JUNB and either YAP or TAZ on a transfected 
.CC-BY 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted February 18, 2021. ; https://doi.org/10.1101/2021.02.18.431832doi: bioRxiv preprint 
 
10 
plasmid-borne locus containing six AP-1 motif sites shows increased fold-enrichment in 
transformed cells, while this does not occur on a control plasmid locus lacking the AP-1 sites 
(Figure 5F).  
 
YAP and TAZ are recruited via AP-1 and, to a lesser extent, STAT3 motifs 
 Transcriptional co-activators such as YAP and TAZ are ultimately recruited to genomic sites 
by sequence-specific DNA-binding proteins.  Thus, motifs enriched in YAP and TAZ 
binding sites suggest which proteins mediate the recruitment. In ER-Src cells, JUNB binds 
primarily to AP-1 sequence motifs, indicative of a direct protein-DNA interaction, whereas 
STAT3 binding sites contain either STAT3 or AP-1 motifs, indicating that STAT3 can bind 
directly to DNA or indirectly via interactions with AP-1 proteins (Ji et al., 2019).  To 
determine which motifs are enriched at YAP and TAZ sites, we compared the frequency of 
sequence motifs from the HOCOMOCO and JASPAR catalogs within YAP/TAZ target sites 
against comparable DNase hypersensitive sites that are not bound by YAP/TAZ. 
 As expected from YAP/TAZ being a co-activator of TEAD proteins, ~30% of 
YAP/TAZ binding loci contain TEAD motifs (Figure 6A), and the TEAD motif is the most 
significantly enriched motif within YAP/TAZ sites (Figure 6B). Interestingly, and in accord 
with the direct interaction of JUNB and YAP/TAZ, a comparable number of YAP/TAZ 
target sites contain AP-1 motifs (Figure 6A).  However, the fold-enrichment of AP-1 motifs 
at YAP/TAZ sites vs. control loci is only modest (Figure 6B), presumably due to AP-1 
factors being involved in a wide range of pathways. YAP and TAZ target sites also contain 
STAT3 motifs, albeit at much lower frequency (13%) and minimal enrichment over control 
loci. Importantly, all the TEAD, AP-1, and STAT3 motifs are centered around YAP/TAZ 
peak summits (Figure 6C), as expected for direct recruitment of YAP/TAZ by these DNA-
binding transcription factors.  In accord with previous observations (Zanconato et al., 2015), 
~6% of YAP/TAZ target sites contain both AP-1 and TEAD motifs (Figure 6D), a higher 
frequency than expected by chance (Figure 6E).  In contrast, NF-κB motifs are not enriched 
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or centered at YAP/TAZ target sites (Figure 6A-C).  Taken together with the direct protein-
protein interactions, these results strong suggest that, in addition to TEADs, AP-1 proteins 
and (to a lesser extent) STAT3 can directly recruit YAP/TAZ to genomic sites.     
 
CEBP motifs are enriched at YAP/TAZ target sites, and TAZ-specific sites are enriched 
for ETS motifs and depleted for AP-1 motifs 
 Unexpectedly, the motif recognized by the CEBP family of transcription factors occurs in 
~25% of YAP/TAZ sites with an enrichment over control sites that is second-most behind 
that of TEAD motifs (Figure 6B).  CEBP motifs also occur very close to YAP/TAZ peak 
summits (Figure 6C), suggesting that one or more CEBP proteins can recruit YAP/TAZ to 
target sites. In addition, CEBP motifs are strongly enriched within TEAD binding regions 
(Figure 4-figure supplement 1), and CEBP and TEAD motifs co-occur at YAP/TAZ sites at 
more than five times the rate that they co-occur in control regions (Figure 6E).  Although 
CEBP proteins have not been studied in the ER-Src model, it is noteworthy that CEBPβ 
ranks fourth among transcription factors predicted to be important for transformation (just 
behind JUNB, STAT3, and FOSL1), and siRNA-mediated depletion of CEBPβ reduces the 
level of transformation (Ji et al., 2018).  Lastly, a minority of YAP/TAZ binding sites lack 
AP-1, STAT3, TEAD, or CEBP motifs, suggesting that other DNA-binding proteins can also 
recruit these co-activators. 
 Analysis of ~450 TAZ-specific sites (Figure 4) indicates that the aforementioned motifs 
are not significantly enriched (Figure 4-figure supplement 1, lower-right panel; there are 
insufficient YAP-specific sites to perform this analysis).  Instead, motifs for ETS family 
proteins are strongly enriched and the AP-1 motif is significantly depleted at TAZ-specific 
sites compared to control sites.  This observation strongly supports the idea that TAZ-specific 
sites represent a biologically distinct subset from YAP/TAZ shared sites that differ with 
respect to the mechanism of co-activator recruitment and the genes that are affected.   
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YAP and TAZ co-occupy sites with JUNB and STAT3 in a triple-negative breast cancer 
cell line 
 To provide independent support of our results, we performed ChIP-seq in a triple-negative 
breast cancer cell line (MDA-MB-231).  Binding sites for YAP, TAZ, STAT3, JUNB, and 
TEAD (Table S1B) show considerable overlap with binding sites in ER-Src cells, although 
many sites appear cell-line specific (Figure 6-figure supplement 1). In MDA-MB-231 cells, 
YAP and TAZ have similar binding sites (Figure 6-figure supplement 2A) that frequently 
coincide with TEAD, AP-1, and STAT3 binding sites (Figure 6-figure supplement 2B, C).  
The percentage of YAP/TAZ binding sites associated with AP-1, TEAD, and STAT3 motifs 
are comparable in both cell lines (compare Figure 6A with Figure 6-figure supplement 3A, 
B), and roughly half of the YAP/TAZ target sites lack these motifs.  These motifs are 
strongly enriched very near YAP/TAZ peak summits (Figure 6-figure supplement 3C), and 
similar ratios of motif co-occurrences within YAP/TAZ sites are observed in both cell lines 
(Figure 6-figure supplement 3D).  Lastly, the 267 TAZ-specific sites in MDA-MB-231 cells 
are enriched for ELF/ETS-family motifs (Figure 6-figure supplement 3E). Thus, the binding 
profiles of these factors, individually and in combination, are very similar in both cell lines.   
 Interestingly, there are differences between the two cell lines with respect to how 
YAP/TAZ is recruited to target loci.  At YAP/TAZ target sites, the enrichment of CEBP 
motifs in ER-Src cells is not observed in MDA-MB-231 cells (Figure 6-figure supplement 
3A, B).  Conversely, motifs recognized by the RUNX tumor suppressor are significantly 
enriched MDA-MB-231 cells (Figure 6-figure supplement 3B), but not in ER-Src cells.   
Thus, the putative recruitment of YAP/TAZ by CEBP proteins and RUNX appears to be cell-
type-dependent.  This specificity could be due to differences in levels or post-translational 
modifications of the recruiting proteins, and it is likely to cause cell-type-specific differences 
in gene expression.  
 
Different classes of YAP/TAZ sites are associated with different categories of genes 
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 We asked whether subsets of YAP/TAZ binding sites in different cell lines or recruited by 
different transcription factors regulate biologically distinct subsets of genes.  Of the 14,851 
genes having a YAP/TAZ binding site within 2 kb of a TSS, 42% have a YAP/TAZ site in 
both cell lines, while 40% and 18% are specific to MDA-MB-231 and ER-Src, respectively 
(Figure 6-figure supplement 4A). Of 9,690 target genes with a proximal YAP/TAZ site in 
ER-Src cells, a core set of 1,562 were associated with binding sites for all four of YAP, TAZ, 
JUNB, and STAT3 (Figure 6-figure supplement 4B), and 6,806 (70%) were associated with a 
YAP/TAZ site with a candidate recruiting motif (Figure 6-figure supplement 4C).  GO 
analysis for YAP/TAZ target genes specific for ER-Src vs. MDA-MB-231-yielded no 
significant terms at a false discovery rate (FDR) < 5%. However, genes targeted by 
YAP/TAZ sites do differ in their GO enrichment terms based on the presumed recruiting 
motif.  Sites with an AP-1, CEBP, or TEAD motif are enriched for ontology terms related, 
respectively, to development, inflammation, and actin cytoskeletal organization at FDR < 5% 
(Figure 6-figure supplement 4D, Table S3), Terms related to cell adhesion and signal 
transduction are shared between these three classes, albeit at mild enrichment.  No 
significantly enriched GO terms are observed for YAP/TAZ sites with STAT3 motifs (Table 
S3). 
 
A core set of genes is regulated by YAP, TAZ, STAT3, and JUNB 
 To identify genes regulated by YAP, TAZ, JUNB, STAT3, or TEAD proteins, we 
individually depleted these factors by siRNA-mediated knockdown in tamoxifen-treated ER-
Src cells. RNA-seq analysis identifies between 1,000 and 4,000 differentially expressed 
genes for each condition as compared with a control siRNA (FDR < 5%; Figure 7A-B). 
Roughly equal number of genes show increased or decreased expression with the 
directionality of differential expression nearly always preserved among factors (Figure 7A-
C).  In accord with previous results (Ji et al., 2018), there is significant overlap between the 
differentially expressed genes identified for each factor, with a  majority of YAP- or TAZ-
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affected genes being affected by at least one other factor (Figure 7A-C). We identified a core 
set of genes that are affected by all of YAP, TAZ, JUNB, and STAT3 (Figure 7A). Another 
core set of 292 genes, of which 149 decrease in expression and 143 increase, are affected by 
YAP, TAZ, and TEADs (Figure 7B). Notably, binding of these transcription factors is 
significantly more frequent at promoters of these core genes than at randomly generated 
control sets of protein-coding genes (Figure 7D; p-value < 0.01 for all factors). 
 
YAP/TAZ gene signatures are associated with poor prognosis in triple-negative breast 
cancers 
 To determine the clinical significance of YAP/TAZ target genes in breast cancer samples, we 
first defined gene signatures impacted by YAP/TAZ/STAT3/JUNB or YAP/TAZ/TEAD 
(Table S4).  For the YAP/TAZ/STAT3/JUNB set, we defined three gene signatures using the 
following criteria. The first set are target genes of YAP, TAZ, and JUNB in transformed 
condition that are also target genes of STAT3 in the transformed condition but not the non-
transformed condition (i.e. near a tamoxifen-induced STAT3 peak). The second set are target 
genes of YAP, TAZ, and JUNB in the tamoxifen-treated condition that also have an AP-1 
motif. The third set consists of genes from set 2 that are differentially expressed upon 
depletion of JUNB and either YAP or TAZ. For the YAP/TAZ/TEAD set, we defined the 
equivalents of sets 2 and 3 above, using TEAD peaks and motifs rather than JUNB peaks and 
AP-1 motifs. 
 The TCGA Invasive Breast Carcinoma Dataset includes 1,108 breast cancer samples 
from 1,101 patients with follow-up information, of which 116 are triple-negative breast 
cancers. For each signature, we computed a gene signature score (GSS) for each patient and 
then divided patients into low (GSS <0) and high (GSS > 0) gene signature expression (low 
and high risk).  We evaluated the clinical significance of each gene signature by performing 
Kaplan-Meier analysis on overall survival, both on the entire set of patients and on subsets of 
patients with luminal A, luminal B, HER2+, and triple-negative breast cancer (TNBC) types. 
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 The higher GSS groups for all three YAP/TAZ/STAT3/JUNB gene signatures are 
associated with a significantly shorter overall survival than the lower GSS group in TNBC 
patients (p value = 0.01, 0.01, and 0.04; Figure 7E-G). In contrast, survival was not 
significantly different for any of the three signatures for luminal A, luminal B, or HER2+ 
patients (Figure 7-figure supplement 1A-C). In addition, there is no significant difference in 
overall survival for the two YAP/TAZ/TEAD sets for any subset of cancer patients (Figure 7-
figure supplement 2).  As a control, we randomly selected a matched number of genes for 
each gene signature, and none these random gene signatures show significant differences in 
overall survival for any breast cancer subtype or for the entire cohort (Figure 7-figure 
supplement 1D-F show TNBC).  These findings suggest the targeted gene signatures of 
YAP/TAZ and STAT3/JUNB complex are associated with poor prognosis in TNBC patients, 
which may have potential clinical application.  
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YAP and TAZ are transcriptional co-activators of AP-1 proteins and STAT3 
 YAP and TAZ, the major effectors of Hippo signal transduction pathway (Piccolo et al., 
2014; Totaro et al., 2018; Ma et al., 2019), play critical roles in cancer initiation, progression, 
metastasis, and chemo-resistance in cancer therapy (Johnson and Halder, 2014; Yu et al., 
2015; Zanconato et al., 2016).  YAP/TAZ are transcriptional co-activators that are recruited 
by the TEAD family of transcription factors (Piccolo et al., 2014; Totaro et al., 2018; Ma et 
al., 2019; Moya and Halder, 2019).  Here, we show that YAP and TAZ are important for 
transformation in ER-Src cells, which is mediated by an epigenetic switch involving an 
inflammatory regulatory network controlled by the joint action of NF-κB, STAT3, and AP-1 
transcription factors (Iliopoulos et al., 2009; Iliopoulos et al., 2010; Ji et al., 2018; Ji et al., 
2019).  In this cellular model, YAP and TAZ co-associate with TEAD proteins at many 
target sites.  
         Here, we provide multiple lines of evidence demonstrating that YAP and TAZ are also 
transcriptional co-activators of STAT3 and AP-1 proteins.  First, YAP and TAZ co-
immunoprecipitate with JUNB and STAT3 in nuclear extracts.  Second, all direct pairwise 
interactions between YAP or TAZ with JUNB or STAT3 are observed with proteins 
expressed in E. coli.  The WW1 domain of YAP and the WW domain of TAZ are critical for 
these interactions and for transformation, but they are dispensable for the interaction with 
TEAD proteins.  Third, YAP and TAZ co-associate with JUNB and/or STAT3 at many target 
sites with peak summits very close together. Similar results are observed in a triple-negative 
breast cell line (MDA-MB-231).  Fourth, YAP/TAZ target sites coincide with AP-1 and, to a 
lesser extent, STAT3 motifs.  Indeed, the frequency of AP-1 motifs among YAP/TAZ target 
sites is comparable to that of TEAD motifs.  Fifth, sequential ChIP experiments directly 
indicate that YAP/TAZ co-occupy target sites with JUNB and STAT3.  
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Specificity of YAP and TAZ recruitment to target sites 
 Although YAP and TAZ directly interact with STAT3 and JUNB, the specificity of 
YAP/TAZ association with genomic sites is complex and poorly understood.  YAP/TAZ are 
only recruited to a subset of genomic regions bound by STAT3 and/or AP-1, indicating that 
the direct physical interactions are not sufficient for recruitment.  With respect to the target 
sites and hence the DNA-bound proteins, YAP/TAZ associate with AP-1 and TEAD motifs 
at comparable frequency, but less frequently with STAT3 motifs.  In addition, STAT3 and 
AP-1 proteins directly interact, co-associate with many genomic regions through AP-1 motifs 
and affect the expression of common genes (Ji et al., 2019).  Thus, it is difficult to determine 
the contributions of AP-1 proteins and STAT3 to YAP/TAZ recruitment, although these 
DNA-binding activator proteins play a role individually and in combination.  On the other 
hand, NF-κB is not involved in YAP/TAZ recruitment, even though it can act together with 
STAT3 and AP-1 factors to mediate the inflammatory regulatory network involved in 
transformation (Ji et al., 2019).  We presume that, in addition to AP-1 proteins and STAT3, 
YAP/TAZ recruitment to specific genomic regions is influenced by other proteins and/or 
DNA sequences near the AP-1 and/or STAT3 sequence motifs. 
         YAP/TAZ, via its interaction with TEAD proteins, can synergize with AP-1 proteins at 
composite regulatory elements containing both TEAD and AP-1 motifs (Zanconato et al., 
2015).  In this regard, we observe a small subset of YAP/TAZ target sites that contain both 
AP-1 and TEAD motifs.  However, most YAP/TAZ target sites that contain AP-1 or STAT3 
motifs do not contain a TEAD motif and vice versa.  Thus, YAP/TAZ can act as a co-
activator for AP-1 and STAT3 in a manner that is independent of TEAD proteins.  
         Although YAP and TAZ have extremely similar binding profiles, they are not identical.  
In particular, we used two independent analyzes to identify 450 TAZ-specific target sites and 
125 YAP-specific target sites.  Interestingly, the TAZ-specific sites are enriched for ETS 
motifs and depleted for AP-1 motifs; TEAD motifs neither enriched or depleted.  These 
observations suggest an ETS protein(s) can interact specifically (although not necessarily 
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directly) with a region of TAZ that is not found in YAP.  In addition, the TAZ-specific sites 
are enriched as certain classes of genes, suggesting a distinct biological function. 
         Lastly, about half of the YAP/TAZ target sites are not associated with AP-1, STAT3, or 
TEAD motifs suggesting that other transcription factors can recruit YAP/TAZ.  CEBP motifs 
are enriched and frequently observed at YAP/TAZ target sites in ER-Src cells, but not in 
MDA-MB-231 cells.  Conversely, RUNX3 motifs are enriched at YAP/TAZ target sites in 
MDA-MB-231 cells, but not in ER-Src cells.  Such cell-line specificity could be due to 
differences in the amount or activity of the recruiting protein(s) that recognize the motif 
and/or differences in auxiliary proteins that are important for recruitment to these motifs. 
 
YAP/TAZ targets associated with AP-1 proteins and STAT3 have different functions 
and cancer properties from those associated with TEAD proteins 
 The current view is that the biological functions of YAP/TAZ are mediated primarily through 
their interaction and recruitment by TEAD proteins (Piccolo et al., 2014; Totaro et al., 2018; 
Ma et al., 2019; Moya and Halder, 2019). However, our results indicate that a comparable 
number of YAP/TAZ targets involve recruitment by AP-1 proteins and/or STAT3. The gene 
signatures of these two classes of YAP/TAZ targets are different. TEAD-associated sites are 
enriched for genes associated with cell motility and cytoskeletal organization, but they are 
not associated with a significant difference in overall survival for breast cancer patients. In 
contrast, the gene signature of AP-1/STAT3-associated YAP/TAZ targets is not associated 
with cell motility genes but is linked to shorter survival of triple-negative breast cancer 
patients; no overall survival difference is observed for other breast cancer subtypes. Thus, in 
addition to serving as a coactivator for TEAD proteins, YAP and TAZ are also co-activators 
for AP-1 proteins and STAT3, with both classes of target sites and affected genes playing 
important, yet distinct, roles in cancer-related phenotypes and cancer progression. 
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MATERIALS AND METHODS 
 
Cell lines and chemicals 
MCF-10A-ER-Src cells (Iliopoulos et al., 2009; Iliopoulos et al., 2010) were grown in 
DMEM/F12 without phenol red (Thermo Fisher Scientific, 11039-047) + 5% charcoal 
stripped FBS (Sigma, F6765) + 1% pen/strep (Thermo Fisher Scientific, 15140122)+20 
ng/ml EGF (Peprotech, AF-100-15) + 0.5 μg/ml Hydrocortisone (Sigma, H-0888) + 0.1 
μg/ml cholera toxin (Sigma, C-8052) + 10 μg/ml insulin (Sigma, 10516). 1-0.4 μM 
Tamoxifen (Sigma, H7904) + 2-4 μM AZD0530 (Selleck Chemicals, S1006) were used to 
induce the transformation. MDA-MB-231 cells were grown in DMEM (Thermo Fisher 
Scientific, 11995-073) + 10% FBS (Sigma, TMS-013-B) + 1% pen/strep.  
 
Cell transformation assays 
The transformation capacity was measured by growth in low attachment conditions (GILA) 
(Rotem et al., 2015) or in soft agar. For the soft agar assay, 104 cells in culture medium were 
mixed with 0.4% low melting point agarose (VWR, 89125-532) at 370C and seeded on top of 
1% agarose standing layer in 12 well dishes. Colony density was measured 2-3 weeks after 
seeding with images captured by a digital camera (Olympus SP-350; Cam2com). For the 
GILA assay, 2000 cells were seeded into ultra-low attachment surface 96-well plate (Costar, 
3474). 5 days after seeding, sphere cells growing in the low attachment plates were 
quantitated by CellTiter-Glo luminescent cell viability assay (Promega, G7571) using a 
SpectraMax M5 Multi-Mode Microplate Reader (Molecular Devices). Cells growing in 
regular culture dishes were stained using crystal violet and cell density was measured using 
Fiji Image J’s (version 1.52b) measurement function. 
 
CRISPR knockout and siRNA knockdown 
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CRISPR sgRNAs, designed with previously described algorithms (Hsu et al., 2013), were 
cloned into a CRISPR-blasticidin lentiviral plasmid, which was constructed by replacing 
puromycin resistant gene with blasticidin resistant gene of LentiCRISPR V2 plasmid 
(Addgene, #52961). The oligo sequences used to clone into CRISPR vector are: YAP exon 
8—AAACTCTCATCCACACTGTTCAGGC and 
CACCGCCTGAACAGTGTGGATGAGA; TAZ exon 3—
AAACCCCGACGAGTCGGTGCTGGAC and CACCGTCCAGCACCGACTCGTCGGG. 
CRISPR lentiviral plasmids and VSV-G, GP and REV plasmids were transfected into 293T 
cells to produce CRISPR lentivirus. CRISPR lentiviruses infected ER-Src cells for 1 day, and 
cells were selected with 10 μg/ml blasticidin (Thermo Fisher, R21001) for additional 3 days.  
 Oligo siRNAs were purchased from Dharmacon (siGENOME SMART pool) (Table 
S5) and were transfected into ER-Src cells using Lipofectamine RNAiMAX (Thermo Fisher 
Scientific, 13778050). 24 hours after transfection, cells were split and then were treated with 
tamoxifen and AZD0530 (4 μM) for additional 24 hours before the following assays.  
 
Cell Fractionation, Co-IP and Western Blot  
Cell fractionation protocols were similar to the protocols as described before with some 
changes (Wu et al., 2002). Cells were washed with cold PBS, resuspended using buffer A (10 
mM HEPES pH 7.5, 10 mM KCl and 2 mM MgCl2), lysed by grinding 50 times in Wheaton 
A (Wheaton, 357538), and then incubated on ice for 20 minutes. The lysate was placed on 
top of 30 % sucrose and pelleted by spinning at 15000 RPM at 4oC for 10 minutes. After 
removing the supernatant as the cytoplasm fraction, pellets were resuspended in buffer GB 
(20 mM TrisCl pH7.9, 50% glycerol, 75 mM NaCl, 0.5 mM EDTA and 0.35 mM DTT) and 
then mixed with an equal amount of buffer NLB (20 mM HEPES pH7.6, 300 mM NaCl, 7.5 
mM MgCl2, 1% NP40, 1 M Urea, 0.2 mM EDTA and 1 mM DTT) and incubated on ice for 
2 min.  After centrifugation at 15000 RPM for 5 minutes, supernatants representing the 
nucleoplasm fraction were removed, and pellets resuspended using protein lysis buffer (20 
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mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 25 mM 
sodium pyrophosphate, 1 mM NaF, 1 mM β-glycerophosphate, 0.1 mM sodium 
orthovanadate, 1 mM PMSF, 2 μg/ml leupeptin and 10 μg/ml aprotinin). The material was 
sonicated 4x15 seconds using Branson Microtip Sonifier 450 at 60% cycle duty and 4.5 
output and spun at 15000 RPM for 5 minutes to obtain the soluble chromatin fraction.  
 Co-immunoprecipitations were performed as described previously (Ji et al., 2019).  
Briefly, lyates were mixed with antibodies and 10 μl Dynabead protein G (Thermo Fisher 
Scientific, 10004D) in 500 μl co-IP buffer (50 mM Tris PH 7.5, 100 mM NaCl, 1.5 mM 
EGTA and 0.1% Triton X-100), then rotated at 4 0C overnight, and washed with a co-IP 
buffer 8 times. Antibodies used for co-IP and western blot can be found in the Table S5. 
 
qPCR 
RNA was extracted using mRNeasy Mini Kit (Qiagen, No. 217004). 1 μg RNA was 
converted to cDNA using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific, 
18080093). qPCR was running using a 7500 Fast Real-time PCR system (Applied 
Biosystems). qPCR primer sequences can be found in the Table S5. All experiments were run 
independently three times and values of each mRNA were normalized to that of the 36b4 
internal control gene.  
 
ELISA assay for IL-6 secretion 
IL-6 secretion was measured using human IL-6 immunoassay kit (R&D Systems, D6050) as 
per manufacturer’s instructions. Optical density was determined using SpectraMax M5 
Multi-Mode Microplate Reader (Molecular Devices). 
 
Luciferase reporter assay 
The pGL-AP-1 plasmid containing 6 consensus AP-1 binding sites was co-transfected with 
the pRL-CMV plasmid (Promega) into cells using TransIT 2020 transfection reagent (Mirus 
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Bio, MIR5400). A pRL-CMV plasmid expressed Renilla protein and was used as an internal 
transfection control. 24 hours after transfection, cells were split and treated with tamoxifen 
for 24 h to induce transformation. After 3 days, firefly and Renilla luciferase activities were 
determined by Dual-luciferase Reporter Assay kit (Promega, E1910).  To evaluate NF-κB 
activity, pGL4.32 [luc2P/NF-κB-RE/Hygro] (E8491, Promega) and pRL-CMV were co-
transfected into cells and the same protocol followed.   
 
Recombinant proteins and direct interactions by co-IP 
To produce recombinant proteins, YAP, TAZ, STAT3 and JUNB were cloned into pET30 
plasmid. Recombinant proteins were produced in BL21 E. Coli and dialyzed in a neutral 
buffer (150 mM NaCl, 46.6 mM Na2HPO4 and NaH2PO4 pH 8.0). The direct interactions 
among these recombinant proteins were examined in vitro using a similar co-IP procedure as 
mentioned above.  
 
ChIP-seq  
Cells were dual cross-linking with a mixture of 2 mM each of ethylene glycol bis 
(succinimidyl succinate) (EGS) and disuccinimidyl glutarate (DSG) and 1% formaldehyde. 
Chromatin was digested with 60 units MNase (New England Biolabs, M0247S) at 37 0C for 
10 minutes and then sonicated using Branson Microtip Sonifier 450 (4X15 second at output 
4.5 and duty cycle 60%) to the sizes mostly between 150-500 bp. 50 μg chromatin, 
antibodies for transcription factors (listed in Table S5), and 15 μl Dynabead protein G 
(Thermo Fisher Scientific, 10004D) was used for the chromatin immunoprecipitation (ChIP). 
ChIP-seq libraries were sequenced using Hiseq 2000 at the Bauer Core Facility, Harvard.  
 
Sequential ChIP 
Sequential ChIP was performed and analyzed as described previously (Geisberg and Struhl, 
2004; Miotto and Struhl, 2011).  100 μg of chromatin was mixed with 20 μl Dynabead and 
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antibodies (listed in Table S5) in 200 μl ChIP IP buffer (20 mM TrisCl pH 7.5, 140 mM 
NaCl, 2 mM EDTA and 2 mM EGTA), rotated at 4 0C overnight, and sequentially washed 
with 1 ml each of ChIP IP buffer, ChIP wash buffer I (20 mM TrisCl pH 7.5, 140 mM NaCl, 
2 mM EDTA, 2 mM EGTA and 0.5% Triton-100), ChIP wash buffer III (twice, 20 mM 
TrisCl pH 7.5, 250 mM LiCl, 2 mM EDTA, 2 mM EGTA and 0.5% Triton-100) and TE 
buffer. The bound material was eluted by 35 μl sequential ChIP elution buffer (20 mM TrisCl 
pH 7.5, 500 mM NaCl, 2 mM EDTA, 2 mM EGTA 30 mM DTT, 0.1% SDS and cOmplete 
protease inhibitor cocktail (Roche, 11873580001) at 37 0C for 30 minutes. Eluted chromatin 
was subjected to a second ChIP by mixing with 20 μl Dynabeads and antibodies in 200 μl 
ChIP IP buffer and then rotated at 4 0C overnight. Chromatin from the second ChIP were 
washed, eluted, and de-crosslinked. Chromatin obtained from single ChIP and sequential 
ChIP samples were analyzed using qPCR. ChIP primers are listed in Table S5. 
 
ChIP-seq analysis 
FASTQ reads were aligned to the human reference genome (GRCh38) using Bowtie2 
(Langmead and Salzberg, 2012). For post-alignment filter steps, we used samtools-1.9 with 
MAPQ threshold 30 and picard-tools-2.18 to remove low quality and duplicate reads. The 
SPP algorithm with --cap-num-peak 300000 and IDR-2.0.4 (Landt et al., 2012) with --soft-
idr-threshold 0.05 was then used to determine the genomic binding sites of each transcription 
factor. The number of IDR peaks are listed in Table S1. Peaks within 2 kb of a GENCODE 
TSS are denoted as TSS-proximal; others are denoted as distal. DESeq2 (Love et al., 2014) 
was used to define protein-specific peaks between YAP and TAZ with the cutoff log2 fold 
change > 0 and multiple-testing adjusted p-value < 0.05.  
 Occupancy analysis we performed using IDR peaks. We used the MACS2 pileup 
command to generate signal profiles which were smoothed using a 10 base pair Gaussian 
kernel to reduce noise. We then identified summits as the positions within a peak with the 
highest signal value. We adjusted IDR peaks to the summits ± 150 regions to avoid the 
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potential bias due to varied ChIP-seq peak length distribution between transcription factors. 
Bedtools-2.29.2 was used to identify overlapped regions and calculate distance between peak 
summits. 
 We downloaded DNase hypersensitivity sites from the ENCODE Portal (ENCODE, 
2020) for ER-Src cells treated for 24 h with tamoxifen (ENCODE accession 
ENCSR752EPH) and used bedtools intersect to determine that YAP/TAZ are present at 
47,547 MCF10A DHSs. To assess co-occupancy of factors with YAP/TAZ for statistical 
significance, we compared the observed fractions of peak intersection with these YAP/TAZ-
bound DHSs against a control set of 47,547 DNase hypersensitivity sites in ER-Src cells that 
are not bound by YAP/TAZ. We generated the control set as follows: (1) we obtained 
DNase-seq signal Z-scores for 2 million human DHSs from the ENCODE Encyclopedia 
(ENCODE, 2020) in tamoxifen-treated MCF10A cells (ENCODE accession 
ENCSR752EPH); (2) we identified DHSs from this set intersecting YAP/TAZ IDR peaks; 
(3) we selected 47,547 random DHSs from the ENCODE collection with the same Z-score 
distribution as the DHSs which intersect YAP/TAZ IDR peaks; (4) we iteratively replaced 
any randomly selected DHSs which intersected YAP/TAZ peaks with alternative DHSs of 
the same Z-score until none of the 47,547 intersected YAP/TAZ peaks. 
 For motif occurrence analysis, TEAD, JUNB, STAT3, CEBPA, NF-κb motifs were 
downloaded from the HOCOMOCO database (Kulakovskiy et al., 2018). We used FIMO 
(Bailey et al., 2015) to scan the human genome for motif matches with a specific threshold 
for each motif as a function of the information content of the motif. For motif enrichment 
analysis, we downloaded the complete set of transcription factor motifs in the HOCOMOCO 
database (Kulakovskiy et al., 2018) and used FIMO to scan IDR peaks for each transcription 
factor (Machanick and Bailey, 2011). We then generated control DHS sets for each set of 
IDR peaks as described above, scanned these sets for motif occurrences using FIMO, and 
computed enrichment Chi-square p-values for each motif. We used this same workflow for 
TAZ-specific peaks. 
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 GO analysis was performed using GOrilla (Eden et al., 2009).  For YAP/TAZ-specific 
peaks, two different control gene sets were tested: (1) genes proximal to non-specific 
YAP/TAZ peaks and (2) genes proximal to any active DHS in MCF10A cells. The results 
were similar; results from the former approach are reported. For YAP/TAZ peaks separated 
by motif, the complete set of genes proximal to YAP/TAZ peaks was used as the control set. 
For non-specific YAP/TAZ peaks, the complete set of genes proximal to any active DHS in 
MCF10A cells was used as the control set. 
 
RNA-seq analysis 
RNA was prepared used mRNeasy Mini Kit (Qiagen, No. 217004). 0.4 μg total RNA was 
used for RNA-seq library preparation. RNA-seq libraries were generated using TruSeq Ribo 
Profile Mammalian Kit (Illumina, RPHMR12126). RNA-seq libraries were sequenced at 
Bauer Core Facility using Hiseq 2000.  For analysis, we trimmed adapter sequences, 
ambiguous ‘N’ nucleotides (the ratio of “N” > 5%), and low-quality tags (quality score < 20). 
Clean reads were aligned against the GENCODE v30 reference transcriptome (Harrow et al., 
2012) using STAR (Dobin et al., 2013) with the following parameters: 
--outFilterMultimapNmax 20 
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Gene counts were normalized to TPM (transcripts per million RNA molecules) using RSEM 
(Li and Dewey, 2011) with the following parameters: “--estimate-rspd --calc-ci.” Differential 
expression analysis was performed with DESeq2 (Love et al., 2014) with default parameters. 
A separate DESeq2 run was performed for siRNA against each factor, comparing replicates 
treated with the siRNA against the given factor versus replicates treated with the control 
siRNA. DESeq2 was performed independently for tamoxifen-treated MCF10A and ethanol-
treated MCF10A for each siRNA. Genes with a multiple-testing adjusted p-value <0.01 were 
considered to be differentially expressed. 
 To assess whether differential genes were significantly more likely to be directly 
regulated by the transcription factors of interest, we divided differential genes into two 
classes: TF target genes, having an IDR peak for a given factor within 2 kb of any of the 
gene’s transcription start sites based on GENCODE v30 annotations; and non-TF target 
genes, not having a peak within that distance of any TSS. We compared each set of 
differential genes against a control set of the same number of protein coding genes randomly 
selected from the GENCODE annotations. A chi-square p-value was computed for the 
respective fractions of target and non-target genes. 
 
Gene signature and survival analysis in breast cancer samples from TCGA 
TCGA Provisional data, including 1,108 breast cancer samples, were obtained from 
https://www.cbioportal.org. These samples were sub-divided into Luminal A, Luminal B, 
HER2+, and TNBC groups according to ER/PR/HER2 status based on 
immunohistochemistry (Parker et al., 2009; Wallden et al., 2015). We used the lifelines 
Python package to perform Kaplan-Meier survival analysis. Gene signature score (GSS) were 
calculated using this formula: GSS=∑(xi-μi)/σi, where xi is the expression of i gene in patient 
samples; μi is mean of i gene in all patient samples; σi is standard deviation. Low expression 
(low risk) group was GSS<0 and high expression (high risk) group was GSS ≥0 (Adorno et 
al., 2009).  We refined the gene signatures by computing the coefficient of variation (CV) of 
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the expression of all genes among these patients, removing genes with little (CV < 5%) or 
excessive variation (CV > 85%), the latter being likely to be statistical noise (Mar et al., 
2011; Jang et al., 2019), and then filtering out pseudogenes (Table S4).   
 In defining gene signatures, we considered an individual gene to be targeted by a 
transcription factor if a ChIP-seq peak for that factor fell within 2 kb of at least one of its 
transcription start sites from the GENCODE catalog (version 30). We considered an 
individual gene to be differentially expressed following RNAi treatment against a given 
factor if its multiple-testing adjusted p-value from DESeq2 was less than 0.01. 
 Three YAP/TAZ/STAT3/JUNB gene signatures were defined as follows. The first 
signature was defined by (1) identifying all targeted by all three of YAP, TAZ, and JUNB in 
tamoxifen-treated MCF10A cells using the above criteria for ChIP-seq, then (2) filtering 
these to contain only genes which are targeted by STAT3 in TAM-treated MCF10A cells but 
not ETH-treated MCF10A cells based on ChIP-seq. The second signature was defined by (1) 
identifying all genes targeted by all three of YAP, TAZ, and JUNB in tamoxifen-treated 
MCF10A cells using the above criteria for ChIP-seq, then (2) filtering these to contain only 
genes for which the associated YAP/TAZ peaks contain a JUNB motif. The third signature 
was defined by filtering genes from the second signature to require that they be differentially 
expressed following JUNBi treatment and also differentially expressed following either 
YAPi treatment, TAZi treatment, or both. 
 Three YAP/TAZ/TEAD gene signatures were defined as follows. The first signature 
was defined by identifying all genes targeted by all three of YAP, TAZ, and TEAD in 
tamoxifen-treated MCF10A cells using the above criteria for ChIP-seq. The second signature 
was defined by filtering genes from the first signature to contain only genes for which the 
associated YAP/TAZ peaks contain a TEAD motif. The third signature was defined by 
filtering genes from the second signature to contain only genes differentially expressed 
following TEADi treatment and also differentially expressed following either YAPi 
treatment, TAZi treatment, or both. 
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All sequencing data were deposited on National Cancer for Biotechnology Information Gene 
Expression Omnibus (GEO). GSE166943 is the accession number for all the data, with 
GSE166941 being the subset for the ChIP-seq data and GSE166942 for the RNA-seq data. 
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Figure 1. YAP and TAZ facilitate transformation. (A) Western blot for YAP, TAZ, and 
Actin levels in the indicated CRISPR-mediated knockout (KO) strains and the parental cell 
line (Ctrl).  (B) Relative growth in low attachment conditions of the indicated cell lines in 
non-transformed (ETH) and transformed conditions (TAM).  Measurements are relative to 
transformed cells with the CRISPR control, which is defined as 1.0. (C) Number of colonies 
growing in soft agar in the indicated cell lines. (D) Relative growth of the indicated cell lines 
in standard high attachment conditions. (E) Relative growth in low attachment conditions, (F) 
YAP and TAZ protein levels, and (G) relative growth in high attachment conditions of cells 
subjected to siRNA-mediated knockdown of YAP and/or TAZ (YAPi and/or TAZi) of cells 
induced by TAM addition for the indicated times.  Error bars indicate ± SD of 3 replicates 
and * indicates values significantly different (p < 0.05) from the control. 
 
Figure 2. YAP and TAZ regulate STAT3 and JUNB activities during transformation. (A) 
Western blot for the indicated proteins (STAT3-p, is the form phosphorylated at Tyr705) in 
cells treated with the indicated siRNAs and with TAM for the indicated times.  (B) 
Normalized IL-6 mRNA (left) and secreted IL-6 (right) levels in the indicated cells and 
conditions.  (C) Relative AP-1-dependent transcriptional activity in the indicated cells and 
conditions.  (D) Relative NF-κB-dependent transcriptional activity.  Error bars indicate ± SD 
of 3 replicates and * indicates values significantly different (p < 0.05) from the control. 
 
Figure 3. YAP and TAZ, via WW domains, directly interact with STAT3 and JUNB. (A) 
Levels of YAP, TAZ, STAT3 and JUNB in the indicated fractions in non-transformed (E) 
and transformed (T) conditions:  MEK1/2, cytoplasm marker; U1 SnRNAP70, nucleoplasm 
marker; H3, chromatin marker. (B) Co-immunoprecipitation in cellular fractions.  Western 
blot of the indicated proteins upon immunoprecipitation (IP) with antibodies against the 
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indicated proteins or the IgG control.  (C) Co-immunoprecipitation with E. coli-generated 
His-tagged recombinant proteins.  Western blot of the input and immunoprecipitated (IP) 
proteins with antibodies against the indicated proteins.  The input sample contained 10% of 
the amount used for recombinant proteins used for the co-immunoprecipitation. (D) Left 
panels are Western blots of the indicated proteins upon immunoprecipitation with the 
indicated HA-tagged YAP (top) or TAZ (bottom) derivatives or IgG control.  Right panels 
are Western blot of cell extracts prior to immunoprecipitation.  (E) Relative growth in 
conditions of low attachment in cells overexpressing the indicated proteins or empty vector 
(EV) control in parental MCF-10A cells (lacking ER-Src).  Error bars indicate ± SD of 3 
replicates and * indicates values significantly different (p < 0.05) from the control. 
 
Figure 4. YAP and TAZ have highly similar binding profiles, but a subset of binding sites 
are unique to each factor. (A) Correlation (r ~ 0.7) of YAP and TAZ binding signals in non-
transformed (ETH) and transformed (TAM) cells.  Putative YAP- and TAZ-specific sites are 
indicated, respectively, as green and yellow.  (B) YAP and TAZ binding signals in YAP- or 
TAZ-knockout cell lines using an antibody that recognizes both proteins.  (C) Number of 
putative YAP- and TAZ-specific sites (dark colors) confirmed in cells deleted for the 
indicated factor (lighter colors).  (D) Percentage of YAP-specific, TAZ-specific, and shared 
YAP/TAZ sites that are located proximal (light colors) or distal (darker colors) to the 
transcription start site (TSS).  (E) Percentages of TAZ-specific (yellow), YAP-specific 
(green), and YAP/TAZ shared (gray) sites intersecting with STAT3, JUNB, and TEAD sites 
in transformed cells. TAZ- and YAP-specific sites are significantly less likely than shared 
sites to intersect JUNB and TEAD sites (Chi-square p-values YAP/JUNB = 3.2×10-24, 
TAZ/JUNB = 2.1×10-81, YAP/TEAD = 0.002, TAZ/TEAD = 9.7×10-20). 
 
Figure 5. YAP and TAZ co-occupy sites with JUNB and STAT3. (A) Venn Diagrams for the 
intersection of the indicated factor binding sites in transformed cells.  (B) Number of DNase 
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hypersensitivity sites containing a YAP/TAZ peak (light blue) and matched control DHSs 
(dark blue) intersecting STAT3, JUNB, and TEAD sites; YAP/TAZ-associated DHSs are 
significantly more likely to intersect peaks for the three factors (Chi-square p-values <10-100 
for all comparisons). (C) Distance between peak summits for biological replicates or 
combinations of the indicated factors in transformed cells.  (D) Fold-enrichments of 
individual and sequential ChIP at the IL-6 enhancer in untransformed (ETH) and transformed 
(TAM) cells with YAP and either JUNB or STAT3 performed in the indicated order. (E) 
Fold-enrichments of individual and sequential ChIP at the IL-6 enhancer with TAZ and 
either JUNB or STAT3 performed in the indicated order. (F) Fold-enrichments of individual 
and sequential ChIP of the indicated proteins on a plasmid containing either 6 AP-1 motifs or 
a control lacking these motifs (Ctrl).  Error bars indicate ± SD of 3 replicates and * indicates 
values significantly different (p < 0.05) from the control. 
 
Figure 6. YAP/TAZ are recruited by TEAD, AP-1, CEBP proteins, and (to a lesser extent) 
STAT3. (A) Percent of binding regions for the indicated proteins that contain a given DNA 
sequence motif (different colors). (B) Enrichment and p-values for various motifs within 
YAP/TAZ target sites in transformed cells as compared with control sites having similar 
DNase-seq signal profiles. (C) Histogram of all motif locations for TEAD, JUNB, STAT3, 
NF-κB, and CEBPB occurring within 500 bp of a YAP (top) or TAZ (bottom) peak summit 
(defined as position 0). (D) Overlap between YAP and TAZ peaks containing the indicated 
motifs. (E)  Fold-enrichment of the indicated pairwise combinations of motif in YAP/TAZ 
target sites relative to control sites. 
 
Figure 7. Core gene sets regulated by these factors are associated with differences in overall 
survival in triple-negative breast cancer patients. (A) Overlap between genes with decreased 
or increased expression in transformed cells treated with RNAi against YAP, TAZ, STAT3, 
or JUNB as compared with a control RNAi. (B) Same as (A), but comparing expression 
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differences following RNAi against YAP, TAZ, and TEAD. (C) Heatmap showing overlap 
between genes upregulated and downregulated following RNAi; directionality of expression 
change is strongly conserved across RNAi conditions. (D) Number of differentially 
expressed (light blue) and matched random control (dark blue) genes having a binding site 
for the indicated transcription factors within 2 kb of at least one TSS. (E-G) Kaplan-Meier 
survival curves for three YAP/TAZ/STAT3/JUNB gene signatures in patients with high 
(orange) or low (blue) signature scores. 
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SUPPLEMENTARY FIGURE LEGENDS 
 
Figure 2-figure supplement 1. Gene expression in siRNA knockdowns. RNA levels of 
YAP, TAZ, STAT3, and NF-κB1 in non-transformed (ETH) or transformed (TAM) cells 
knocked-down by siRNA (i) of the indicated factors. 
 
Figure 3-figure supplement 1. Interactions of YAP and TAZ with JUNB and STAT3.  (A) 
Levels of the indicated proteins in the cytoplasm or nucleus of non-transformed (E) or 
transformed (T) cells.  LDH-A is a cytoplasm marker and H3 is a nucleus marker. (B) Levels 
of the indicated proteins upon immunoprecipitation (IP) with antibodies (Anti) against the 
indicated proteins and the IgG control.  The Anti-YAP/TAZ antibody recognizes both YAP 
and TAZ. (C) Growth of cells overexpressing the indicated proteins (EV is the empty vector 
control) under conditions of high attachment; n = 3 with error bars: ±SD. 
 
Figure 4-figure supplement 1. Motif enrichment and overlap of ChIP-seq peaks. 
Enrichment of the indicated motifs (different colors) in STAT3, JUNB, TEAD, and TAZ-
specific (i.e. not bound by YAP) binding sites as compared with matched control DNase-
hypersensitive regions in transformed cells.  
 
Figure 5-figure supplement 1. Co-binding of YAP/TAZ with other factors. (A) Intersection 
of various combinations of binding sites for the four factors in transformed cells. The number 
of sites for each factor is indicated and black horizontal bars at the bottom left of the panel. 
(B) Distance between peak summits for biological replicates or combinations of the indicated 
factors in non-transformed cells.  (C) Sequential ChIP of YAP or TAZ with JUNB in the 
indicated orders in untransformed (ETH) and transformed (TAM) cells at the SNX24 and 
MYC loci.  (D) Sequential ChIP of YAP or TAZ with JUNB in the indicated orders in 
untransformed (ETH) and transformed (TAM) cells at the MYC locus. 
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Figure 6-figure supplement 1. Venn diagrams of the overlap of the indicated transcription 
factor binding sites in non-transformed (ETH) and transformed (TAM) ER-Src cells and in 
MDA-MB-231 cells.   
 
Figure 6-figure supplement 2. YAP/TAZ binding sites and their co-binding with other 
factors in MDA-MD-231 cells. (A) Correlation between YAP and TAZ binding levels, with 
YAP-specific (green) and TAZ-specific (yellow) sites highlighted. (B) Intersection of various 
combinations of binding sites for the four factors in ethanol-treated MDA-MB-231 cells. (C) 
Inter-summit distances for biological replicates and pairwise combinations of binding sites in 
MDA-MB-231 cells.  
 
Figure 6-figure supplement 3. YAP/TAZ Motif enrichment and co-binding of YAP/TAZ 
with other factors in MDA-MD-231 cells. (A) Percent of binding regions for the indicated 
proteins that contain a given DNA sequence motif (different colors). (B) Enrichment of 
motifs within YAP/TAZ binding sites as compared with control DHSs. (C) Histogram of all 
motif locations for TEAD, JUNB, STAT3, NF-κB, and CEBPB occurring within 500 bp of a 
YAP (top) or TAZ (bottom) peak summit (defined as position 0). (D) Intersection between 
YAP and TAZ sites containing STAT3, AP-1, and TEAD motifs. (E) Enrichment of motifs 
within TAZ-specific peaks as compared with control DHSs. 
 
Figure 6-figure supplement 4. Genes targeted by YAP/TAZ and associated factors based on 
ChIP-seq data. (A) Target genes of YAP/TAZ as determined by proximity of a TSS to a 
ChIP-seq peak in tamoxifen-treated ER-Src or MDA-MB-231 cells. (B)  Overlap between 
JUNB, STAT3, YAP, and TAZ binding sites in target genes in transformed ER-Src cells (C) 
Overlap between YAP/TAZ target genes having a CEBP, STAT, JUN, or TEAD motif 
proximal to at least one TSS in transformed ER-Src cells. (D) GO enrichment terms for genes 
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targeted by a YAP/TAZ peak containing a CEBP motif (top) or a TEAD motif (bottom) in 
tamoxifen-treated MCF10A cells. 
 
Figure 7-figure supplement 1. Kaplan-Meier survival curves for (A) 
YAP/TAZ/STAT3/JUNB gene signature 1, (B) YAP/TAZ/STAT3/JUNB gene signature 2, 
and (C) YAP/TAZ/STAT3/JUNB gene signature 3 for luminal A (left), luminal B (center), or 
HER2+ (right) breast cancer. (D-F) Kaplan-Meier survival curves for a random control set of 
genes numbering the same as the three YAP/TAZ/STAT3/JUNB gene signatures in triple-
negative breast cancer. 
 
Figure 7-figure supplement 2. Kaplan-Meier survival curves for (A) YAP/TAZ/TEAD gene 
signature 1, (B) YAP/TAZ/TEAD gene signature 2 for luminal A, luminal B, HER2+, and 
triple-negative breast cancer patient cohorts. 
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SUPPLEMENTARY TABLE LEGENDS 
 
Table S1. Correlation between (A) biological replicates and (B) number of binding sites of 
the indicated proteins in ER-Src (ethanol or tamoxifen; wild-type and YAP or TAZ knockout 
(KO) and MDA-MB-231 cells.. 
 
Table S2. Enriched GO categories for YAP-specific, TAZ-specific, or shared YAP/TAZ 
target genes. 
 
Table S3. Enriched GO categories for YAP/TAZ target sites containing the indicated motifs.  
 
Table S4. Gene signatures for the indicated categories of YAP/TAZ target sites. 
 
Table S5. siRNAs, antibodies, qPCR primers, ChIP-seq primers, and list of datasets.   
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Figure 5 TEAD1 STAT3JUNBYAP/TAZ
C
Number of YAP/TAZ peaks intersecting 
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